A Phase IV, Randomised, Multi-centre, Efficacy and Safety Study Examining the Effect of Induction Dosing with the combination of peginterferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Infected with Hepatitis C Genotype 1.

Trial Profile

A Phase IV, Randomised, Multi-centre, Efficacy and Safety Study Examining the Effect of Induction Dosing with the combination of peginterferon Alfa-2a and Ribavirin in Patients with Chronic Hepatitis C Infected with Hepatitis C Genotype 1.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms CHARIOT
  • Sponsors Roche
  • Most Recent Events

    • 06 May 2016 Time frame of primary end point changed from week 42 to week 72.
    • 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry record ACTRN12605000488606).
    • 13 May 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top